Novel treatments to help patients with central nervous system disorders



BioArctic´s mission is to improve quality of life for patients suffering from central nervous system disorders. Patients with neurodegenerative diseases like Alzheimer’s and Parkinson’s disease will be treated with antibodies targeting the misfolded proteins in these disorders. BioArctic has developed a technology platform that has proven to be successful when the company's first drug candidate antibody (BAN2401) for Alzheimer´s disease was developed. BioArctic's technology is now applied to other CNS disorders like Parkinson’s disease, and novel antibodies are being developed.

Protein aggregation/misfolding

The key molecular event in these diseases is today believed to be protein misfolding and aggregation. The spreading of soluble aggregates leads to neuronal dysfunction, cell death, brain damage and symptoms of disease. Each neurodegenerative disease is characterised through its unique aggregated protein. The hallmark of Alzheimer's disease is amyloid-ß (Aß), whereas α-synuclein is the signature protein of Parkinson's disease and Dementia with Lewy bodies (DLB). Other examples of misfolded proteins causing diseases are SOD1 in Amyotrophic Lateral Sclerosis (ALS), huntingtin in Huntington's disease, and the prion protein in Creutzfeldt-Jacob's disease. Also systemic amyloidosis like AL amyloidosis, transthyretin amylodosis and secondary amyloidosis due to amyloid formed by serum amyloid A are caused by aggregated proteins. An attractive treatment strategy is to eliminate these toxic proteins.


Antibody technology

BioArctic has a proprietary technology by which therapeutic monoclonal antibodies can be developed. These antibodies are highly specific for aggregated/misfolded proteins involved in disorders such as Alzheimer's and Parkinson's disease.

Therapeutic mechanism

The antibodies developed by BioArctic have the unique property to reduce soluble, toxic aggregated/misfolded proteins in the brain. Reduction of these toxic proteins is believed to be of significant clinical value.

Oligomers/protofibrils are visulized with Atomic Force Microscopy.
Picture provided by Dr. Martin Ingelsson.